Health insurers promise artificial intelligence will result in frictionless care, but providers have concerns about denials and lack of transparency.
Novo Nordisk and Eli Lilly still enjoy advantages, but there could be early cracks in their dominance, analysts say.
The treatment, called COMP360, is intended to treat severe depression. It could be the first psilocybin-based medicine on the market.
American Medical Association CEO John Whyte on the threat posed by AI scams using the faces and voices of real physicians.
Health care needs an ethical framework for determining who gets pain medication during drug shortages.
Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.
